Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

ClinicalTrials.gov ID: NCT02322814

Public ClinicalTrials.gov record NCT02322814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer

Study identification

NCT ID
NCT02322814
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
169 participants

Conditions and interventions

Conditions

Interventions

  • Atezolizumab Drug
  • Cobimetinib Drug
  • Nab-Paclitaxel Drug
  • Paclitaxel Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 11, 2015
Primary completion
Aug 9, 2018
Completion
Sep 16, 2021
Last update posted
Apr 12, 2023

2015 – 2021

United States locations

U.S. sites
11
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Cancer Specialists of North Florida Jacksonville Florida 32256-6932
Mercy Hospital, a Campus of Plantation General Hospital Miami Florida 33133
Florida Hospital Cancer Inst Orlando Florida 32804
Florida Cancer Research Institute Plantation Florida 33324
Cancer Treatment Centers of America Newnan Georgia 30265
Ingalls Memorial Hospital Harvey Illinois 60426
Montefiore Einstein Cancer Center The Bronx New York 10461
Magee Womens Hospital Pittsburgh Pennsylvania 15213
Medical University of South Carolina Charleston South Carolina 29425
Avera Cancer Institute Sioux Falls South Dakota 57105
Northwest Medical Specialties Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02322814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2023 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02322814 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →